Wegovy weight-loss drug maker worth more than Danish GDP

This week's share surge on news that Wegovy comes with heart benefit catapulted Novo Nordisk's market capitalisation above €385bn. Picture: Wegovy.com
The shares surged this week in the wake of news that the firm's weight-loss drug Wegovy comes with a heart benefit. The gain catapulted the market capitalisation above 2.87 trillion kroner (€385bn), more than Denmark’s 2022 gross domestic product, and means Novo is vying for the title of Europe’s most valuable company.